Gilead Sciences, Inc. has submitted a sNDA to the FDA and a Type II variation to the EMEA for marketing approval of Viread for the treatment of chronic hepatitis B in adults. Viread is currently approved in the U.S. and EU for the treatment of HIV as part of a combination antiretroviral therapy. The submissions include data from two Phase III trials, Studies 102 and 103, in patients chronically infected with the hepatitis B virus (HBV). These studies evaluate the safety, efficacy and tolera...